SCHEMBL1248933

SCHEMBL1248933

CS(=O)(=O)Nc1cccc(Cl)c1-c1nc2ccc(C(=O)Nc3cccc(Cl)c3)cc2[nH]1

nearest known ligand 0.64

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
DGAT1 O75907 7/20 0.64
HDAC6 Q9UBN7 2/20 0.48
MEN1 O00255 4/20 0.48
KMT2A Q03164 4/20 0.48
KDM4E B2RXH2 1/20 0.48
ALDH1A1 P00352 1/20 0.48
HPGD P15428 1/20 0.48
HTT P42858 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
ADORA3 P0DMS8 1/20 0.47
ADORA2A P29274 1/20 0.47
ADORA2B P29275 1/20 0.47
ADORA1 P30542 1/20 0.47
KDR P35968 2/20 0.47
NR2E3 Q9Y5X4 2/20 0.46
CYP3A4 P08684 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1249380 0.88 DGAT1 (0.67) DGAT1HDAC6MEN1KMT2AKDM4E
SCHEMBL1249424 0.88 DGAT1 (0.82) DGAT1HDAC6MEN1KMT2AKDM4E
SCHEMBL3167498 0.85 DGAT1 (0.53) DGAT1HDAC6MEN1KMT2A
SCHEMBL1250039 0.83 DGAT1 (0.71) DGAT1HDAC6MEN1KMT2AKDM4E
SCHEMBL1250909 0.82 DGAT1 (0.77) DGAT1HDAC6MEN1KMT2AKDM4E
SCHEMBL1250221 0.81 DGAT1 (0.85) DGAT1HDAC6KDRNR2E3CYP3A4
SCHEMBL1248766 0.80 DGAT1 (0.66) DGAT1HDAC6MEN1KMT2AALDH1A1
SCHEMBL1250402 0.80 DGAT1 (0.75) DGAT1HDAC6MEN1KMT2AKDM4E
SCHEMBL1250216 0.80 DGAT1 (0.66) DGAT1HDAC6MEN1KMT2AKDM4E
SCHEMBL1250454 0.80 DGAT1 (0.66) DGAT1HDAC6MEN1KMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8222248-B2 Organic compounds NOVARTIS AG (CH) 2012-07-17 US disclosed
US-20110046133-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2011-02-24 US disclosed
US-20110046133-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2011-02-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110046133-A1 ORGANIC COMPOUNDS DGAT1, DGAT2, SOAT1 DGAT1 1/4885HDAC6 1155/4885MEN1 3613/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.